Keyphrases
Prostate Cancer
100%
Treatment Landscape
100%
Next-generation Sequencing
100%
Clinical Utilization
100%
Clinical Actionability
100%
PARP Inhibitor (PARPi)
41%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
16%
Patients with Prostate Cancer
16%
Chi-square
16%
Median Time
8%
Systemic Therapy
8%
Clinical Data
8%
Direct Therapy
8%
Metastatic Disease
8%
Electronic Medical Records
8%
Single Center
8%
Single-center Retrospective Study
8%
Inhibitor Treatment
8%
Testing Data
8%
Number of Days
8%
Early Use
8%
Post-approval Changes
8%
Later-line Treatment
8%
Homologous Recombination Repair
8%
Olaparib
8%
Preapproval
8%
Medicine and Dentistry
Prostate Cancer
100%
Next Generation Sequencing
100%
PARP Inhibitor
41%
Metastatic Carcinoma
8%
Electronic Patient Record
8%
Retrospective Study
8%
Systemic Therapy
8%
Homologous Recombination
8%
Recombination Repair
8%
Olaparib
8%
Immunology and Microbiology
Prostate
100%
Next Generation Sequencing
100%
Homologous Recombination
8%
Electronic Medical Record
8%
Recombination Repair
8%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
71%
Metastasis
14%
Retrospective Study
14%
Olaparib
14%